LGM Pharma Enhances Testing Services for Drug Development
LGM Pharma, a frontrunner in the realm of tailored Active Pharmaceutical Ingredient (API) and Contract Development and Manufacturing Organization (CDMO) services, has taken a significant step forward by expanding its Analytical Testing Services (ATS). This advancement includes the introduction of endotoxin and rapid sterility testing capabilities, designed specifically to cater to the needs of drug developers.
Response to Growing Demands in the Pharmaceutical Industry
In an ever-evolving pharmaceutical landscape, there is a pressing demand for swift and dependable testing of sterile compounds. With the installation of cutting-edge equipment at its facility, LGM Pharma has transformed its service offerings. The incorporation of rapid sterility testing drastically reduces incubation times from the usual 14 days to a mere five days. This remarkable advancement enables drug sponsors to expedite product market entry while ensuring unwavering confidence in quality and compliance with regulatory standards.
The Importance of Rapid Testing Services
The introduction of automated result readouts is a game-changer, bolstering data integrity and minimizing the risk of human error. Leveraging PCR-based sterility detection, this service significantly increases detection throughput, enhances sensitivity, and ensures paramount accuracy. These improvements align with LGM Pharma's dedication to delivering high-quality and safe drug products.
Investment in Quality and Compliance
Shailesh Vengurlekar, Senior Vice President of Quality and Regulatory Affairs at LGM Pharma, expressed the company's steadfast commitment to client satisfaction: "Our investment in these new testing capabilities highlights our dedication to providing the highest quality services to our customers, ranging from small to large pharmaceutical companies. Many of our clients, particularly in compounding pharmacies, are seeking a reliable partner capable of delivering rapid, precise, and cost-effective testing for their sterile products. This expansion allows us to better serve their needs."
Regulatory Compliance and Accessibility
Endotoxin and rapid sterility testing are critical components for pharmaceutical enterprises involved in developing sterile and injectable products. By making these services accessible, especially to smaller companies with tight budgets, LGM Pharma believes it is playing a vital role in supporting businesses navigating the complex regulatory requirements like the 503(a), 503(b), and 505(b)(2) pathways. These pathways necessitate rigorous quality control to satisfy FDA and global standards.
Commitment to Innovation and Client Needs
Diem Hoang, Director of Quality Assurance, emphasizes LGM Pharma’s unyielding focus on quality and compliance: "Our expertise in analytical testing ensures our clients receive accurate and reliable results. The recent expansion of our testing services guarantees that our clients' products meet the stringent standards necessary for regulatory approvals." This commitment to quality is demonstrated through the acquisition of new technology and capabilities, keeping LGM Pharma at the forefront of industry innovation.
Streamlining Pharmaceutical Development
Integrating new endotoxin and rapid sterility testing capabilities into its portfolio not only strengthens LGM Pharma’s position as a comprehensive provider of pharmaceutical development solutions but also simplifies the supply chain for its clients. This enhancement empowers clients by streamlining production timelines and reducing costs linked to out-of-specification results and repeated testing.
Contact and Learn More
For those interested in exploring LGM Pharma’s innovative testing services or requesting a quote, they can reach out to LGM Pharma directly via email or explore their offerings through their website.
About LGM Pharma
LGM Pharma stands as a leading contract development and manufacturing organization (CDMO), providing extensive API sourcing and drug product solutions across the pharmaceutical, biotechnology, and compounding pharmacy domains. The company assists its clients through every phase of drug product development, facilitating a seamless progression from API sourcing to commercialization. With a broad global network of qualified API partners, LGM Pharma helps clients optimize supply chain management and distribution. Their services encompass API sourcing, formulation development, analytical method development, stability testing, and regulatory submissions. The organization is deeply committed to quality assurance and boasts a solid regulatory compliance record, providing expert regulatory insights to its customers. LGM Pharma prides itself on delivering personalized solutions and comprehensive manufacturing capabilities that mitigate risks and hasten market entry.
Frequently Asked Questions
What new capabilities has LGM Pharma introduced?
LGM Pharma expanded its testing services by adding endotoxin and rapid sterility testing capabilities, enhancing their analytical services significantly.
How does rapid sterility testing benefit drug developers?
This testing reduces incubation times from 14 days to just five days, allowing drug developers to bring their products to market faster while ensuring quality compliance.
Who can benefit from LGM Pharma's testing services?
Both large and small pharmaceutical companies, as well as compounding pharmacies, can access these high-quality and reliable testing services.
Why is compliance important for pharmaceutical testing?
Compliance ensures that drug products meet stringent regulatory standards, which is essential for gaining FDA approval and ensuring patient safety.
How does LGM Pharma ensure data integrity in testing?
Automated result readouts in their testing process enhance data integrity and lower the chances of human errors, providing accurate and reliable results.
